Skip to main content

Table 4 Multivariate Cox proportional hazards on radiotherapy, ECOG performance score, serum albumin and 21 tumor markers

From: Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis

Tumor Marker

p* <

HR†

CA125

0.033

1.37 (1.02 - 1.99)

CEA

0.037

1.43 (1.03 - 1.82)

CPA1

0.082

1.43 (0.60 - 4.33)

Adam8

0.14

1.29 (0.96 - 2.14)

Erbb2

0.17

1.42 (0.86 - 2.34)

SLPI

0.24

1.38 (0.92 - 1.81)

MESO

0.28

1.31 (0.56 - 1.81)

EGFR

0.34

1.61 (0.81 - 2.34)

VEGF

0.43

1.13 (0.75 - 1.35)

TNF

0.48

1.14 (0.61 - 2.71)

IL-7

0.54

1.07 (0.66 - 1.88)

CTGF

0.55

1.08 (0.80 - 2.14)

CA19-9

0.64

0.96 (0.84 - 1.38)

EpCam

0.51

1.12 (0.80 - 1.62)

Galectin

0.51

1.28 (0.83 - 1.54)

MIF

0.95

0.99 (0.85 - 1.36)

OPN

0.68

1.12 (0.80 - 1.57)

CHI3L1

0.8

0.96 (0.82 - 1.13)

IGF2

0.68

1.12 (0.64 - 1.97)

CA15-3

0.98

1.01 (0.80 - 1.57)

IL-1

0.5

1.12 (0.69 - 1.33)

  1. *- p-value derived from a univariate Cox proportional hazards model accounting for the effect of tumor marker only on prognosis
  2. † - Hazard ratio derived from univariate Cox proportional hazards model. Parenthetical values denote 95% confidence interval.